Linical : (Delayed)FY 2022 Financial Results Briefing(2,410kb)

*Please note that this translation is to be used solely as reference.

In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.

FY 2022 Financial Results Briefing

Monday, May 23, 2022

Kazuhiro Hatano

President and CEO

Linical Co.,Ltd.

TSE Prime 2183

Contents

1. Business Orveview

P. 2 ~ 4

2. Financial Results for FY ended March 2022 P. 5 ~ 15

3. Forecasts of FY ending March 2023

P. 16 ~ 18

4. Management Strategy

P. 19 ~ 28

1. Business Overview

Global CRO from Japan

• Global Linical Network

			Beijing			Canada
			Korea		Illinois
Germany
		Tokyo
Spain	Czech		Shang	San Diego	New York
Republic		Osaka
Poland	France	India	hai	(Linical Headquarters)	Florida
Hungary	Romania
UK Netherlands			Taiwan		Mexico
	Italy			Philippines
		Singapore				Brazil
			Indonesia
	South Africa				Australia	Chile
					Argentina
				Red: Headquarters Orange: Branch Pink: Subsidiary Blue: Subsidiary Green: CRA Employment ash: Under consideration as base

Linical aims to be a global CRO originating in Japan and contributes to new drug development as a drug
development professional
We currently operate in 18 countries and regions, and can provide services in more than 20 countries and
regions worldwide	3

Trends in Sales and Operating Income since Establishment

• Sales and Operating Income since Establishment (Billions of Yen)

		Net Sales		Operating Profit
Net Sales
100				November 2014
				European CRO
				Acquisition of
				Nuvisan

			Operating
April 2018		115	Profit
	50
U.S. CRO
Accelovance
Acquisition	113	109

10340

91

83

					January 2014	77	30
			March 2013
		October 2008	Korea CRO
		First Section	P-Pro Acquisition
50		Mothers Listed	of the Tokyo				20
				Stock			49	COVID-19
	June 2005	Exchange
	36	37
	Establishment
				25	31			10
			24
		20
	1	13
0	6						0

(Fiscal Year) 2006/3 2007/3 2008/3 2009/3 2010/3 2011/3 2012/3 2013/3 2014/3 2015/3 2016/3 2017/3 2018/3 2019/3 2020/3 2021/3 2022/3

We achieved our highest ever sales while the impacts of COVID-19 remained in each region

Operating profit has also recovered to pre-COVID-19 levels​

4